Jennifer S. Guimbellot

Associate Professor

University of Arkansas for Medical Sciences

faculty

18 h-index 66 pubs 932 cited

Research Areas

Cystic Fibrosis Research Pharmacological Effects and Toxicity Studies Molecular Biology Techniques and Applications Child and Adolescent Health Health disparities and outcomes CRISPR and Genetic Engineering Genomics and Rare Diseases Diet and metabolism studies

Links

ORCID Lab Website UAMS TRI Profile

Is this your profile? Verify and claim your profile

OverviewAI-generated summary

Jennifer S. Guimbellot's research focuses on cystic fibrosis (CF), particularly the efficacy and application of CFTR modulator therapies. Her work investigates the use of elexacaftor/tezacaftor/ivacaftor in lung transplant recipients and its combination with other medications like tacrolimus. Guimbellot has also explored the quantification of these therapies in human plasma and cellular lysates, as well as plasma concentrations in CF patients. Her publications include studies on CFTR function in relation to modulators, using nasal epithelial organoid swelling as a metric. Additionally, her research extends to genetic correction of CFTR mutations using prime editing in induced pluripotent stem cells and their derived airway epithelial cells. Guimbellot also examines outcomes for children with inconclusive CF diagnoses or CFTR-related metabolic syndrome and has investigated the acceptability and associations of electronic screening for social needs in pediatric pulmonary clinics. She has 66 publications with 932 citations and an h-index of 18. Guimbellot collaborates with A. Chalamalla, with whom she shares 13 publications.

Metrics

h-index: 18
Publications: 66
Citations: 932

Selected Publications

Predicting Cavg of CFTR Modulators Using Sparse Sampling: Evaluating Single and Multiple Time Points with Machine Learning Approaches (2025) DOI
Predicting Cavg of CFTR Modulators Using Sparse Sampling: Evaluating Single and Multiple Time Points with Machine Learning Approaches (2025) DOI
Predicting Cavg of CFTR Modulators Using Sparse Sampling: Evaluating Single and Multiple Time Points with Machine Learning Approaches (2025) DOI
EPS2.03Highly-effective CFTR modulation and lung development by age, gender, and height among children with cystic fibrosis (2025) DOI
P018 Single measurement quantification and modeling of elexafactor, tezacaftor and ivacaftor in adults: overlap between full and reduced dosing (2025) DOI
One- and Two-timepoint Sparse Sampling is Highly Predictive of Average Plasma Concentration of CFTR Modulators (2025) DOI
Tobacco Smoke Exposure Decreases Longitudinal Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis (2025) DOI
Modulator Concentrations Significantly Contribute to Variability in Sweat Chloride Results After Therapy With Elexacaftor/Tezacaftor/Ivacaftor (2025) DOI
Ivacaftor for Chronic Obstructive Pulmonary Disease: Results from a Phase 2, Randomized Controlled Trial (2024) DOI
Literary evidence of the impact of nonbiological risk factors on CRMS/CFSPID: A scoping review (2024) DOI
Differential distribution of ivacaftor and its metabolites in plasma and human airway epithelia (2024) DOI
Pharmacokinetic variability of CFTR modulators from standard and alternative regimens (2024) DOI